Video

Dr. Markman on Timing of BSO in Patients With Ovarian Cancer

Author(s):

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer, or at an increased risk for the disease, should undergo a bilateral salpingo-oophorectomy (BSO).

There is less definitive data on when it is appropriate for patients to undergo a BSO, Markman explains, though the likely age range is between 35 and 45 years old. It may be more fitting to have the procedure at a later age due to side effects associated with BSO, such as surgical menopause, heart disease, osteoporosis, and psychosocial issues.

Additionally, there is increasing evidence that patients with BRCA1/2 mutations will have a very different lifetime risk of ovarian cancer, Markman adds.

Related Videos
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marshall Posner, MD
Renee Saliby, MD, MSc
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD